Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Carrying extra weight may mean less relief from RA meds. A large meta-analysis of nearly 12,000 patients found that higher BMI was linked to significantly reduced responses to JAK inhibitors in rheumatoid arthritis. The more severe the obesity, the weaker the treatment effect — suggesting clinicians may need to factor in weight when planning RA therapy.
Carrying extra weight may mean less relief from RA meds
A major new meta-analysis published in The Lancet Rheumatology found that patients with rheumatoid arthritis (RA) who have higher BMIs respond significantly worse to JAK inhibitors — a widely used class of RA medications. The study pooled individual patient data from 16 phase 3 randomized controlled trials involving nearly 12,000 patients.
The findings showed a clear dose-response relationship: the higher the BMI, the weaker the treatment effect. Patients with obesity class 3 (BMI ≥ 40) had a 22% lower likelihood of achieving meaningful clinical improvement compared to those at a healthy weight. Importantly, no similar BMI-related trend was seen in placebo groups, pointing to a specific interaction between weight and JAK inhibitor efficacy.
By the Numbers
Why it matters: These findings push clinicians to treat BMI not just as a background characteristic, but as an active factor in RA treatment planning. Patients with obesity may need tailored strategies — whether that's weight management support, dose adjustments, or alternative therapies — to achieve optimal outcomes.
